Zurich, 23^rd of September 2025: Xlife Sciences AG (SIX: XLS) today published its Half-Year Report 2025. The first half of the year was marked by consistent preparation for the capital markets. With the filing of the F-4 prospectus by VERAXA Biotech AG, a decisive step toward a NASDAQ listing has been taken and a milestone for both VERAXA and Xlife Sciences as an incubator has been reached.

The full Half-Year Report 2025 of Xlife Sciences AG is available for download in the «Financial Reports» section at https://www.xlifesciences.ch/en/news-and-key-figures.

Operational Highlights in H1 2025  

• VERAXA Biotech AG: With its proprietary Bi-Targeted Antibody Cytotoxicity (BiTAC) and Antibody-Drug Conjugates (ADC) platform, VERAXA addresses one of the greatest challenges in modern cancer therapies, the «on-target, off-tumor» toxicity. The planned NASDAQ listing opens access to global investor circles and underscores the scalability of its business model.


• Firstgene Life Sciences & Hovione: The development of an innovative virus-like particle (VLP) platform for gene therapy against liver cancer represents a project with international impact.


• Alliance in Korea: Cooperation with JIPYONG LLC and JIPYONG IP to connect regional life sciences companies to global capital markets and strengthen presence in Asia.


• Digital Health & Precision Oncology: Memorandum of Understanding with Huraypositive Corp. and OncoMASTER Inc. to build presence in two fast-growing future fields.

These developments highlight the internationalization of the Xlife Sciences platform and prepare portfolio companies for capital market–relevant success.

Key Financial Figures H1 2025  

From services provided to our project companies, we generated revenues of CHF 354.321.- in the first half of 2025 (as of 30 June 2025) (previous year: CHF 349.818.-). Earnings per share (undiluted) amounted to CHF -0.53.- (previous year: CHF 0.08.-). Total assets stood at CHF 536.3 million (previous year: CHF 509.9 million). Equity amounted to CHF 391.9 million (previous year: CHF 367.0 million). Cash and cash equivalents as of the end of June 2025 were CHF 51.553.- (end of June 2024: CHF 99.776.-).

Outlook for H2 2025

The priorities for the second half of the year are clearly defined:

1. The support of the NASDAQ listing of VERAXA Biotech AG is the most important capital markets project in the company’s history.
2. Advancing the Firstgene/Hovione partnership toward clinical implementation.
3. Operationalizing alliances in Asia with a focus on digital health and precision oncology.
4. Expansion of the presence and the partnering program in the USA through Dr. Frank Plöger, in order to further strengthen access to investors and strategic partners.
5. Presentation of the clinical study by saniva diagnostics GmbH, which will provide important momentum for the validation and commercialization of the NeuroMex project.
6. Consolidation and focus of the portfolio to allocate resources specifically to the most value-generating projects and increase the efficiency of the incubation model.

Oliver R. Baumann, CEO of Xlife Sciences AG, commented: «The upcoming NASDAQ listing of VERAXA is more than a single event, it is exemplary proof of the functionality of our incubation model. Together with our international partners, we are laying the foundation for sustainable value creation and global visibility.»

Financial calendar

Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch, 
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange